https://doi.org/10.55788/0145d681
There has been a rapid evolution of therapies for hereditary myopathies, with new molecular approaches offering promising advances [1]. Antisense oligonucleotides and ERT have already radically changed diseases such as Duchenne muscular dystrophy (DMD) and Pompe disease. Additionally, RNA toxicity reduction strategies in myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy are emerging as potential therapies.
A historical randomised study involving 90 patients with late-onset Pompe disease evaluated the impact of biweekly intravenous alglucosidase alfa (20 mg/kg) over 78 weeks [2]. Results showed significant improvements in the 6-minute walk test and stabilisation of forced vital capacity (FVC). The study concluded that alglucosidase alfa improves walking distance and maintains pulmonary function over 18 months.
More recently, the COMET trial compared the ‘next-generation ERT’ avalglucosidase alfa with alglucosidase alfa in 100 treatment-naïve late-onset Pompe disease (LOPD) patients [3]. The primary outcome was the change in FVC% from baseline to week 49. Avalglucosidase alfa demonstrated clinically meaningful improvements in respiratory function and ambulation, proving non-inferior to alglucosidase alfa with no safety concerns reported.
Further analysis from the COMET trial revealed sustained clinical outcomes for patients on avalglucosidase alfa, with FVC% stabilisation over 145 weeks [4]. Disease-specific and general patient-reported outcomes indicated significant improvements in daily activities, disease symptoms, respiratory function, and mobility. These long-term results have led to a new EPOC consensus paper on the use of ERT for LOPD [5].
In parallel with COMET, the PROPEL trial assessed cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in LOPD patients [6]. Despite not achieving statistical superiority in improving the 6MWT distance, cipaglucosidase alfa plus miglustat showed potential for long-term efficacy and safety, warranting further investigation.
Prof. Toscano also presented a study on safety and patient satisfaction of home-based intravenous ERT for Pompe disease and mucopolysaccharidosis type I during the COVID-19 pandemic [7]. The findings support home therapy as a viable alternative, maintaining treatment compliance and safety.
To conclude, Prof. Toscano summarised the promising developments and ongoing challenges in the treatment of myopathies. He underscored the importance of personalised and long-term treatment strategies. There is still a need for reliable biomarkers to monitor disease progression and therapeutic efficacy in clinical trials.
- Toscano A. The landscape of new treatments in hereditary myopathies. 10th EAN Congress, 29 June–2 July 2024, Helsinki, Finland.
- van der Ploeg AT, et al. N Engl J Med 2010 Apr 15;362(15):1396-406.
- Diaz-Manera J, et al. Lancet Neurol. 2021 Dec;20(12):1012-1026.
- Kishnani PS, et al. JAMA Neurol. 2023 Jun 1;80(6):558-567.
- Schoser B, et al. Eur J Neurol. 2024 Jun 14:e16383.
- Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037.
- Toscano A, et al. Orphanet J Rare Dis. 2023 Oct 27;18(1):338.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Under investigation: Opioid use and the risk for dementia Next Article
Therapeutic advancement in spinal muscular atrophy »
« Under investigation: Opioid use and the risk for dementia Next Article
Therapeutic advancement in spinal muscular atrophy »
Table of Contents: EAN 2024
Featured articles
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Treatment escalation and de-escalation in late-onset MS
Diagnostics and Disease Management in Neurology
What is the value of transcranial ultrasound for diagnosing Parkinson’s disease?
How to achieve goal-concordant care in severe acute brain injury?
Changing treatment landscape in myasthenia gravis
Stroke and Vascular Events
High risk for recurrent vascular events in young stroke patients
Anticoagulation or antiplatelet as secondary prevention for cancer-related strokes?
Multiple Sclerosis
Treatment escalation and de-escalation in late-onset MS
How different are late onset and adult onset MS really?
Advances in Neurostimulation
Vagal nerve stimulation for the reduction of cognitive impairment in Alzheimer’s disease
Spinal cord stimulation for chronic pain: state-of-affairs in 2024
Innovations in VNS and DBS for refractory epilepsy
Genetic and Molecular Therapies
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Therapeutic advancement in spinal muscular atrophy
Therapeutic advancement in Pompe disease
Neurological Risk Factors and Predictive Tools
Under investigation: Opioid use and the risk for dementia
Novel tool to predict outcomes in anti-NMDAR encephalitis
Related Articles
November 30, 2020
Midlife blood pressure tied to white matter hyperintensities
August 18, 2021
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com